Outlook Therapeutics Inc - Warrants - Series A (18/02/2022)
OTLKW
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.03M
Close$
Share Statistics
| Market cap | $30.03 Million |
|---|---|
| Enterprise Value | $-7,227,234,967,508.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.79 |
| Beta | 0 |
| Outstanding Shares | 81,836,000 |
Return
| Return on Equity | 130.71% |
|---|---|
| Return on Assets | -173.11% |
| Return on Invested Capital | 277.14% |
Valuation & Multiples
| P/E Ratio | -0.98 |
|---|---|
| PEG | 1.08 |
| Price to Sales | 0.0 |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | -4.69 |
| Enterprise Value to EBIT | 0.15 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.07 |
| Debt to Equity | -0.02 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Outlook Therapeutics Inc
8 employees
CEO: Lawrence Kenyon